clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Stomach Diseases D013272 7 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Skin Neoplasms D012878 12 associated lipids
Colitis D003092 69 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Arthritis D001168 41 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Abscess D000038 13 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Gastritis D005756 27 associated lipids
Heart Failure D006333 36 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Rodent Diseases D012376 4 associated lipids
Osteomyelitis D010019 10 associated lipids
Pancreatitis D010195 10 associated lipids
Skin Ulcer D012883 6 associated lipids
Cysts D003560 4 associated lipids
Urination Disorders D014555 9 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Bradycardia D001919 13 associated lipids
Endometriosis D004715 29 associated lipids
Myocardial Infarction D009203 21 associated lipids
Proteinuria D011507 30 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Arteriosclerosis D001161 86 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Fractures, Open D005597 3 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Fan W et al. An unusual case of folliculitis spinulosa decalvans. 2016 Cutis pmid:27814407
Miftahussurur M et al. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. 2016 BMC Microbiol. pmid:27809767
Sancak S et al. Intestinal blood flow by Doppler ultrasound: the impact of clarithromycin treatment for feeding intolerance in preterm neonates. 2016 J. Matern. Fetal. Neonatal. Med. pmid:26135789
Uehara H et al. Comparison of the Anti-angiogenic and Anti-inflammatory Effects of Two Antibiotics: Clarithromycin Versus Moxifloxacin. 2016 Curr. Eye Res. pmid:26125497
Ohe M et al. A case of lupus nephritis treated with clarithromycin, tacrolimus, and glucocorticoids. 2016 Kaohsiung J. Med. Sci. pmid:27638410
Phaw NA and Tsai HH Eosinophilic gastroenteritis: a challenge to diagnose and treat. 2016 BMJ Case Rep pmid:27613263
Plate A [Not Available]. 2016 Praxis (Bern 1994) pmid:27606919
Huh CW et al. Early Attempts to Eradicate Helicobacter pylori after Endoscopic Resection of Gastric Neoplasm Significantly Improve Eradication Success Rates. 2016 PLoS ONE pmid:27588679
Watanabe M et al. Saturated fatty acids and fatty acid esters promote the polymorphic transition of clarithromycin metastable form I crystal. 2016 Int J Pharm pmid:27553780
Nagashima A et al. Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells. 2016 Antimicrob. Agents Chemother. pmid:27550358
Cosme A et al. Antimicrobial Susceptibility-Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance. 2016 Helicobacter pmid:25982426
Ozeki K et al. Association of Hay Fever with the Failure of Helicobacter pylori Primary Eradication. 2016 Intern. Med. pmid:27374672
Campillo A et al. [Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection]. 2016 Med Clin (Barc) pmid:27374029
Khashei R et al. High rate of A2142G point mutation associated with clarithromycin resistance among Iranian Helicobacter pylori clinical isolates. 2016 APMIS pmid:27357065
Alarcón-Millán J et al. Clarithromycin resistance and prevalence of Helicobacter pylori virulent genotypes in patients from Southern México with chronic gastritis. 2016 Infect. Genet. Evol. pmid:27355861
Khonche A et al. Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial. 2016 Drug Res (Stuttg) pmid:27351245
Büchsel M et al. A case of septic arthritis caused by a Mycoplasma salivarium strain resistant towards Ciprofloxacin and Clarithromycin in a patient with chronic lymphatic leukemia. 2016 Diagn. Microbiol. Infect. Dis. pmid:27342785
Lin LC et al. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. 2016 World J. Gastroenterol. pmid:27340362
Abd-Elsalam S et al. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. 2016 Medicine (Baltimore) pmid:27310977
De Francesco V et al. Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication. 2016 J Gastrointestin Liver Dis pmid:27308644
Oberhofer E [Quadruple therapy is more effective against H. pylori]. 2016 MMW Fortschr Med pmid:27155683
Mayor S Short term increase in neuropsychiatric events is seen with H pylori treatment containing clarithromycin. 2016 BMJ pmid:27143325
Shokri-Shirvani J et al. Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. 2016 Aliment. Pharmacol. Ther. pmid:27137738
Wong AY et al. Association Between Acute Neuropsychiatric Events and Helicobacter pylori Therapy Containing Clarithromycin. 2016 JAMA Intern Med pmid:27136661
Zollner-Schwetz I et al. Primary resistance of Helicobacter pylori is still low in Southern Austria. 2016 Int. J. Med. Microbiol. pmid:27134190
Georgopoulos SD et al. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. 2016 Eur. J. Intern. Med. pmid:27134145
Kim JS et al. Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial. 2016 Gut Liver pmid:27114421
Manniello MD et al. Aerodynamic properties, solubility and in vitro antibacterial efficacy of dry powders prepared by spray drying: Clarithromycin versus its hydrochloride salt. 2016 Eur J Pharm Biopharm pmid:27106605
Swaminathan A et al. Treating children for drug-resistant tuberculosis in Tajikistan with Group 5 medications. 2016 Int. J. Tuberc. Lung Dis. pmid:26970156
Wong IC Author's reply to Blake. 2016 BMJ pmid:26957514
Todo K et al. Severe Helicobacter pylori gastritis-related thrombocytopenia and iron deficiency anemia in an adolescent female. 2016 Ann. Hematol. pmid:26957356
Iyer G and Alexander GC Editorialists' reply to Blake. 2016 BMJ pmid:26957321
Blake Z Study provides insufficient evidence of a link between clarithromycin and myocardial infarction. 2016 BMJ pmid:26955978
Seyama S et al. Clarithromycin Resistance Mechanisms of Epidemic β-Lactamase-Nonproducing Ampicillin-Resistant Haemophilus influenzae Strains in Japan. 2016 Antimicrob. Agents Chemother. pmid:26953210
Ji Z et al. The Association of Age and Antibiotic Resistance of Helicobacter Pylori: A Study in Jiaxing City, Zhejiang Province, China. 2016 Medicine (Baltimore) pmid:26937912
Murakami K et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. 2016 Gut pmid:26935876
Park JY et al. Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA. 2016 Dig. Dis. Sci. pmid:26923948
Trac MH et al. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. 2016 CMAJ pmid:26903359
Miglietta F et al. A rare case of Saprochaete capitata fungemia in a critical ill patient without hematologic and oncological disorders. 2016 Rev Esp Quimioter pmid:26785226
Raymond J et al. Diagnosis of Helicobacter pylori recurrence: relapse or reinfection? Usefulness of molecular tools. 2016 Scand. J. Gastroenterol. pmid:26784882
Kefeli A et al. Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial. 2016 Bosn J Basic Med Sci pmid:26773183
Iyer G and Alexander GC Cardiovascular risks associated with clarithromycin. 2016 BMJ pmid:26769796
Wong AY et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. 2016 BMJ pmid:26768836
Hirama T et al. PCR-Based Rapid Identification System Using Bridged Nucleic Acids for Detection of Clarithromycin-Resistant Mycobacterium avium-M. intracellulare Complex Isolates. 2016 J. Clin. Microbiol. pmid:26739154
Radheshi E et al. Postmortem diagnosis of anaphylaxis in presence of decompositional changes. 2016 J Forensic Leg Med pmid:26735898
Jain SK et al. Lectin-Conjugated Clarithromycin and Acetohydroxamic Acid-Loaded PLGA Nanoparticles: a Novel Approach for Effective Treatment of H. pylori. 2016 AAPS PharmSciTech pmid:26566630
Di Giulio M et al. In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy. 2016 Scand. J. Gastroenterol. pmid:26554617
Djennane-Hadibi F et al. High-Level Primary Clarithromycin Resistance of Helicobacter pylori in Algiers, Algeria: A Prospective Multicenter Molecular Study. 2016 Microb. Drug Resist. pmid:26554340
Chen CH et al. Mycobacterium abscessus complex bacteremia due to prostatitis after prostate biopsy. 2016 Indian J Tuberc pmid:27998503
Gehlot V et al. Low prevalence of clarithromycin-resistant Helicobacter pylori isolates with A2143G point mutation in the 23S rRNA gene in North India. 2016 J Glob Antimicrob Resist pmid:27530837
Xuan SH et al. Detection of clarithromycin-resistant Helicobacter pylori in clinical specimens by molecular methods: A review. 2016 J Glob Antimicrob Resist pmid:27436390
Siddiqui TR et al. Emerging trends of antimicrobial resistance in Helicobacter pylori isolates obtained from Pakistani patients: The need for consideration of amoxicillin and clarithromycin. 2016 J Pak Med Assoc pmid:27339574
Lee J et al. A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM. 2016 J. Matern. Fetal. Neonatal. Med. pmid:26441216
Shimizu T and Suzaki H Past, present and future of macrolide therapy for chronic rhinosinusitis in Japan. 2016 Auris Nasus Larynx pmid:26441370
Apostolopoulos P et al. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. 2016 Scand. J. Gastroenterol. pmid:26435055
Hollitt A et al. Cat scratch disease of the parotid gland. 2016 Arch. Dis. Child. pmid:26403943
Mosdósi B et al. Severe acrocyanosis precipitated by cold agglutinin secondary to infection with Mycoplasma pneumoniae in a pediatric patient. 2017 Croat. Med. J. pmid:29308834
Zhang X and Hu C Selecting optimal columns for clarithromycin impurity analysis according to the quantitative relationship of hydrophobic subtraction model. 2017 J Pharm Biomed Anal pmid:28024686
Paul P et al. Capillary electrophoresis with capacitively coupled contactless conductivity detection method development and validation for the determination of azithromycin, clarithromycin, and clindamycin. 2017 J Sep Sci pmid:28683179
Morimoto K et al. A Laboratory-based Analysis of Nontuberculous Mycobacterial Lung Disease in Japan from 2012 to 2013. 2017 Ann Am Thorac Soc pmid:27788025
Wong AYS et al. Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis. 2017 Drug Saf pmid:28397186
Baluch A et al. Successful management of Mycobacterium haemophilum lower extremity cutaneous infection in a matched-unrelated donor stem cell transplant recipient. 2017 Transpl Infect Dis pmid:27775824
Aziz DB et al. Rifabutin Is Active against Mycobacterium abscessus Complex. 2017 Antimicrob. Agents Chemother. pmid:28396540
Maruyama M et al. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Eradication: A Randomized Controlled Trial. 2017 Can J Gastroenterol Hepatol pmid:28349044
Brouqui P et al. Old antibiotics for emerging multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB). 2017 Int. J. Antimicrob. Agents pmid:28336312
Xu YF et al. and Antibacterial Activities of Patchouli Alcohol, a Naturally Occurring Tricyclic Sesquiterpene, against Helicobacter pylori Infection. 2017 Antimicrob. Agents Chemother. pmid:28320722
Yang YJ et al. Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes. 2017 Ann. Med. pmid:28266875
Geng X et al. The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of Helicobacter pylori by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471. 2017 Antimicrob. Agents Chemother. pmid:28242673
Park SM et al. Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. 2017 J. Gastroenterol. Hepatol. pmid:27505301
Yoon HY et al. Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. 2017 Int. J. Tuberc. Lung Dis. pmid:28826448
Yoon H et al. Eradication Downregulates Cellular Inhibitor of Apoptosis Protein 2 in Gastric Carcinogenesis. 2017 Gut Liver pmid:27282269
Santos RP et al. induced rash and mucositis: a recently described entity. 2017 BMJ Case Rep pmid:28830900
Kwon S et al. [The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in Eradication]. 2017 Korean J Gastroenterol pmid:28830132
Nanishi E et al. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study. 2017 J Am Heart Assoc pmid:28684643
Boal Carvalho P et al. Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting? 2017 Acta Med Port pmid:28550827
Shah SA et al. Clarithromycin inhibits TNF-α-induced MUC5AC mucin gene expression via the MKP-1-p38MAPK-dependent pathway. 2017 Int. Immunopharmacol. pmid:28550735
Osaki T et al. Usefulness of detection of clarithromycin-resistant Helicobacter pylori from fecal specimens for young adults treated with eradication therapy. 2017 Helicobacter pmid:28544222
Chang CT et al. Antibiotic treatment of zebrafish mycobacteriosis: tolerance and efficacy of treatments with tigecycline and clarithromycin. 2017 J. Fish Dis. pmid:28422304
Jakubů V et al. Trends in the Minimum Inhibitory Concentrations of Erythromycin, Clarithromycin, Azithromycin, Ciprofloxacin, and Trimethoprim/Sulfamethoxazole for Strains of Bordetella pertussis isolated in the Czech Republic in 1967-2015. 2017 Cent. Eur. J. Public Health pmid:29346850
Vaz AM et al. Capsule endoscopy in the diagnosis of disseminated complex infection. 2017 BMJ Case Rep pmid:29167222
Lee H et al. Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial. 2017 Trials pmid:29149904
Fremlin GA et al. Clarithromycin, rifampicin and fusidic acid triple combination therapy for chronic folliculocentric pustulosis of the scalp. 2017 Clin. Exp. Dermatol. pmid:28691163
Andere NMRB et al. Clarithromycin as an Adjunct to One-Stage Full-Mouth Ultrasonic Periodontal Debridement in Generalized Aggressive Periodontitis: A Randomized Controlled Clinical Trial. 2017 J. Periodontol. pmid:28671507
Sotto RB et al. Sub-lethal pharmaceutical hazard tracking in adult zebrafish using untargeted LC-MS environmental metabolomics. 2017 J. Hazard. Mater. pmid:28623724
Adachi T et al. Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori. 2017 Oncology pmid:29258111
Moon SH et al. Novel Linear Lipopeptide Paenipeptins with Potential for Eradicating Biofilms and Sensitizing Gram-Negative Bacteria to Rifampicin and Clarithromycin. 2017 J. Med. Chem. pmid:29136469
Carneiro MDS et al. Lack of association between rrl and erm(41) mutations and clarithromycin resistance in Mycobacterium abscessus complex. 2017 Mem. Inst. Oswaldo Cruz pmid:29091138
Feng L et al. Removal of antibiotics during the anaerobic digestion of pig manure. 2017 Sci. Total Environ. pmid:28628813
Freyne B and Curtis N Mycobacterium gordonae Skin Infection in an Immunocompetent Child. 2017 Pediatr. Infect. Dis. J. pmid:28403059
Bustamante-Rengifo JA et al. Effect of treatment failure on the CagA EPIYA motif in strains from Colombian subjects. 2017 World J. Gastroenterol. pmid:28373764
Marin AC et al. Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. 2017 Drugs pmid:28361211
Holmberg LA et al. Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin. 2017 Acta Haematol. pmid:28355602
Smith S et al. The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. 2017 Eur J Gastroenterol Hepatol pmid:28350745
Mougari F et al. Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. 2017 J. Antimicrob. Chemother. pmid:28333340
Chen PY et al. Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. 2017 Aliment. Pharmacol. Ther. pmid:28074519
Zamani M et al. Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection. 2017 Aliment. Pharmacol. Ther. pmid:28074507
Chey WD et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. 2017 Am. J. Gastroenterol. pmid:28071659
Fernández Martos R et al. Acute psychotic episode secondary to Helicobacter pylori eradication treatment. 2017 Rev Esp Enferm Dig pmid:28071063
Ko J et al. Delayed onset Mycobacterium intracellulare keratitis after laser in situ keratomileusis: A case report and literature review. 2017 Medicine (Baltimore) pmid:29390522
Takeuchi S et al. Hypotension induced by the concomitant use of a calcium-channel blocker and clarithromycin. 2017 BMJ Case Rep pmid:28069789